September 19, 2019
El médico oncólogo y presidente de ISPOR Brasil, Dr. Stephen Stefani, em su participación en ISPOR LatAm hizo un resumen de los diez puntos culminantes de […]
January 8, 2019
AS REPORTED in The New England Journal of Medicine by Scott J. Antonia, MD, PhD, of H. Lee Moffitt Cancer Center and Research Institute, and colleagues, the phase III PACIFIC […]
May 10, 2018
In patients with gastric cancer who receive chemotherapy before gastrectomy, resulting in downstaged disease (cN+ ypN0), overall survival is similar to that of patients with natural […]
May 10, 2018
The FDA approved the combination of dabrafenib (Tafinlar, Novartis) and trametinib (Mekinist, Novartis) for the treatment of unresectable or metastatic anaplastic thyroid cancer (ATC) with the BRAF V600E […]
May 10, 2018
The FDA approved daratumumab (Darzalex, Janssen) in combination with VMP (bortezomib [Velcade, Millennium], melphalan and prednisone) for the treatment of patients with newly diagnosed multiple myeloma […]
May 10, 2018
Novartis announced today that the US Food and Drug Administration (FDA) has approved Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) for the adjuvant treatment of patients […]
May 10, 2018
Novartis today announced the US Food and Drug Administration (FDA) has approved Kymriah® (tisagenlecleucel) suspension for intravenous infusion for its second indication – the treatment of […]